Background The link between low-density lipoprotein cholesterol (LDL-C) levels and dementia risk is poorly understood, with conflicting evidence on the role of LDL-C and the impact of statin therapy ...

The diagnosis of post-encephalitic Parkinsonism is rarely entertained today. In this paper we discuss eight recent patients, six of whom presented in the last 20 years, that conform to the diagnosis ...

Background: Some ganglioside complexes (GSCs) are target antigens for serum antibodies in patients with Guillain–Barré syndrome (GBS). Anti-GSC antibodies may be associated with particular clinical ...

Objective To investigate the effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex (DLPFC) on working memory performance, while ...

Background: Two professional painters experienced significant changes in their art as the main consequence of minor stroke located in the left occipital lobe or thalamus. Methods: The features of this ...

Background and objectives: Hyperekplexia and the stiff-man syndrome (SMS) are both conditions with exaggerated startle suggesting abnormal brainstem function. Investigation of brainstem reflexes may ...

Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies ...

Conclusion Autoimmune encephalitis-associated antibodies are a common request at the NHNN Neuroimmunology laboratory. The cost of tests over the last 5 years has been nearly £100000 to identify 10 ...

Objective: To assess the risk of recurrence of cerebral venous and sinus thrombosis (CVST) during subsequent pregnancy and puerperium in women with previous cerebral venous occlusive disease. Methods: ...

RG6102 is a bispecific 2+1 monoclonal antibody (mAb) under development for the treatment of Alz- heimer’s disease (AD). It combines the anti-amyloid beta antibody gantenerumab with a transferrin ...

Thoracic-onset amyotrophic lateral sclerosis (T-ALS) is a rare subform, affecting only 3% of all patients with amyotrophic lateral sclerosis (ALS).1 In order to facilitate a better understanding of ...

Objective Little is known about disease-modifying treatments (DMTs) for multiple sclerosis (MS) and infection risk in clinical practice. We examined the association between DMTs and infection-related ...